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Introduction 
     
According to the Parkinson’s Disease (PD) Foundation, PD is a 
progressive neurodegenerative disorder that affects 
predominately dopamine-producing neurons in an area of the 
brain called the substantia nigra (“Understanding parkinson’s,” 
2019). This impairment of neurons causes individuals with PD to 
have low levels or completely lack the neurotransmitter 
dopamine in the brain (“Understanding parkinson’s,” 2019). 
Dopamine plays a critical role in regulating motor function and 
movements therefore, lack of dopamine will cause diminished 
coordination and difficulty managing many motor skills 
(“Understanding parkinson’s,” 2019). Bradykinesia (slowness of 
movements), tremor at rest, and muscular rigidity are defined as 
the cardinal triad symptoms seen in PD related to the lack of 
dopamine in the brain (“Understanding parkinson’s,” 2019). 
Dopamine also plays a critical role in cognition and controls 
things like memory and judgment, hence the reason why some 
individuals with PD may suffer cognitive impairment later in the 
disease progression (“Understanding parkinson’s,” 2019). PD is a 
complex, multi-faceted disease (Gopalakrishna & Alexander, 
2015). The etiology remains somewhat unclear, but research 
shows that genetic and environmental factors may play a role in 
the onset of the disease (Capriotti & Terzakis, 2016). There is no 
definitive diagnosis or cure and treatment options must be 
tailored to the individual (Gopalakrishna & Alexander, 2015). 
“Modern therapies and continuous research aim to evaluate the 
pathophysiology of PD and manage symptoms so that patients 
with the disease are living longer with increased quality of life 
(Gopalakrishna & Alexander, 2015, 325).” 
Case Process Signs and Symptoms 
Agrawal, A. (2018, August 11). Typical appearance of 
Parkinson's disease. Retrieved from 
https://www.a4clinics.com/single-post/2018/08/12/5-
Things-to-Know-About-Parkinson’s-Disease 
Underlying Pathophysiology 
Agrawal, A. (2018, August 11). Typical appearance of 
Parkinson's disease. Retrieved from 
https://www.a4clinics.com/single-
post/2018/08/12/5-Things-to-Know-About-
Parkinson’s-Disease 
 
Biercewicz, M., Filipska, K., Rybka, M., Haor, B., 
Glowacka, M., & Kornatowska, K. (2016).  
Nursing problems of patients with parkinson's 
disease: Case report. The Journal of  
Neurological and Neurosurgical Nursing, 5(4), 156-
161. doi:10.15225/PNN.2016.5.4.5 
 
Capriotti, T., & Terzakis, K. (2016). Parkinson 
disease. Home Healthcare Now, 34(6), 300-307.  
doi:10.1097/NHH.0000000000000398 
 
Coterrell, P. (2018). Parkinson's disease: Symptoms, 
treatment options and nursing care. Nursing 
Standard, 33(7), 53-58. doi:10.7748/ns.2018.e11207 
 
Delay the disease. (2017). Retrieved from 
http://www.delaythedisease.com/ 
 
DeMaagd, G., & Philip, A. (2015). Parkinson's disease 
and its management: Part 1: Disease  
entity, risk factors, pathophysiology, clinical 
presentation, and diagnosis. Pharmacy and  
Therapeutics, 40(8), 504-510. Retrieved from  
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4
517533/ 
 
Gopalakrishna, A., & Alexander, S. A. (2015). 
Understanding parkinson disease: A complex and 
multifaceted illness. Journal of Neuroscience Nursing, 
47(6), 320-326.  
doi:10.1097/JNN.0000000000000162 
 
Paillard, T., Rolland, Y., & De Souto Barreto, P. 
(2015). Protective effects of physical exercise in 
alzheimer's disease and parkinson's disease: A 
narrative review. Journal of Clinical Neurology, 
11(3), 212-219. doi:10.3988/jcn.2015.11.3.212 
 
Parkinson's disease. (2018, November 26). Retrieved 
from 
https://labiotech.eu/features/immunotherapy-
parkinsons-disease/ 
 
Understanding parkinson's. (2019). Retrieved May 
29, 2019, from  
https://www.parkinson.org/understanding-
parkinsons 
 
Valera, E., & Masliah, E. (2016). Therapeutic 
approaches in parkinson's disease and related  
disorders. Journal of Neurochemistry, 139(1), 346-
352. doi:10.1111/jnc.13529 
 
Conclusions 
      Watching a parent navigate a life with PD is certainly one of the reasons this 
topic was chosen. By understanding the pathophysiology of the disease, 
learning what to expect as the disease progresses, and becoming 
knowledgeable about treatment options as well as resources that are available 
to provide the best quality of life possible will make the journey through PD a 
little more bearable. Also, research and numbers show that more patients are 
being diagnosed with neurodegenerative diseases like PD (Valera & Masliah, 
2016). More than 10 million people worldwide are living with PD, and 
approximately 60,000 Americans are diagnosed with PD each year 
(“Understanding parkinson’s,” 2019). The World Health Organization (WHO) 
predicts that by 2040, as the population continues to get older, 
neurodegenerative diseases will become the second leading overall cause of 
death following cardiovascular disease (Valera & Masliah, 2016). Advanced 
Practice Nurses (APRN’s) in all settings will likely encounter patients with PD 
and will have a role in clinical monitoring, identifying when problems arise, and 
providing support and resources to their patients with PD as well as to their 
family (Cotterell, 2018). PD can cause significant physical, psychological, and 
social effects for patients (Cotterell, 2018). By understanding the disease and all 
the effects, APRN’s will have the knowledge and resources necessary to provide 
quality care to their patients (Cotterell, 2018). The role of the APRN is critical as 
they work alongside Doctors, Pharmacists, Physical Therapy, Occupational 
Therapy and Nutritionists (Gopalakrishna & Alexander, 2015). By learning and 
understanding the pathophysiology of PD and its disease process, APRN’s have 
the opportunity to help tailor care, minimize symptoms, improve motor 
function, maximize patient outcomes, and provide increased quality of life for 
their PD patients and families (Gopalakrishna & Alexander, 2015). 
 
     The signs and symptoms of PD can vary based on 
the individual and the progression of the disease and 
can be classified as motor symptoms or nonmotor 
symptoms. The classic symptoms are listed below.  
 Motor Signs and Symptoms: 
• Bradykinesia (slowness of movement) 
• Rigidity 
• Tremor at rest 
• Postural instability 
• Shuffling gait 
• Stooped posture 
• Dyskinesia (uncontrolled, involuntary muscle 
movement) 
• Micrographia (small handwriting) 
• Reduced arm swinging 
Nonmotor Signs and Symptoms: 
• Staring appearance/Masked facial expression 
• Flat affect 
• Depression/anxiety 
• Sleep disruption 
• Fatigue 
• Autonomic dysfunction including:  inappropriate 
diaphoresis, orthostatic hypotension, gastric 
retention, constipation, and urinary retention 
• Cognitive impairment 
• Diminished speech volumes 
• Unexplained sensory disturbances (pain, 
impaired smell, and vision) (Capriotti & Terzakis, 
2016). 
 
• While there have not been any concrete causes established, evidence and research suggest  that 
genetic and environmental factors contribute to the development as well as the progression of 
PD (Gopalakrishna & Alexander, 2015).  
• A few of the gene mutations which research has identified to be associated with PD include: 
Alpha-synuclein gene (SNCA), Glucocerebrosidase gene (GBA), and Leucine-rich repeat kinase 2 
(LRRK2) gene loci (DeMaagd & Philip, 2015).  
• Environmental risk factors which research has identified to be associated with the development 
and progression of PD include: Elevated cholesterol, environmental toxins (ie: pesticides), head 
trauma, elevated body mass index (BMI), oxidative stress and the formation of free radicals from 
exposure to numerous carcinogens (DeMaagd & Philip, 2015).  
• The hallmark pathophysiologic processes for PD are the loss of dopaminergic neurons of the 
substantia nigra in the midbrain which are critical for smooth and fluid motor movements and 
the formation or presence of Lewy bodies which contribute to the cognitive impairments 
occasionally seen as the disease progresses into later stages  (Gopalakrishna & Alexander, 2015).  
• Loss of dopaminergic neurons due to Nigrostiatal dopaminergic neurodegeneration in the basal 
ganglia leads to an imbalance between excitation and inhibition pathways in the brain resulting 
in the overall decrease in motor function for PD patients (Gopalakrishna & Alexander, 2015). The 
presence of the nonmotor symptoms of PD supports the involvement of other neurotransmitters 
of the glutamatergic, cholinergic, serotonergic, and adrenergic systems (DeMaagd & Philip, 
2015).  
• There is still much to be discovered regarding the presence of Lewy bodies in PD patients. Some 
research shows that the amount of Lewy bodies found in the Substantia nigra of PD patients with 
dementia is significantly higher than PD patients without dementia. Other research suggests a 
stronger association between cognitive impairment of PD with Lewy body distribution, rather 
than the amount, within the cerebral cortex (DeMaagd & Philip, 2015).  
Significance of Pathophysiology 
Parkinson's disease. (2018, November 26). Retrieved from 
https://labiotech.eu/features/immunotherapy-parkinsons-disease/ 
A 62-year old Caucasian female presents for a routine annual visit. A full 
history and physical is taken and below were the findings: 
 
History: Elevated Cholesterol levels, Osteoporosis, 
 
Chief Complaint: Patient reports that she has had a bilateral upper 
extremity fine tremor for awhile, she reports stiffness in the morning, 
she also states her right arm no longer swings normally like her left arm 
does, her husband pointed this out to her while taking the  dog on their 
morning walks. Otherwise, she feels healthy. 
 
After a full assessment is completed and further discussion with the 
patient, the APRN refers her to a neurologist for further evaluation to 
assist with possible diagnosis of Parkinson’s disease. 
 
Diagnosis: No definitive tests are currently available to confirm a 
diagnosis of Parkinson's disease (DeMaagd & Philip, 2015). Therefore, a 
clinical diagnosis requires a full patient history, assessment of 
symptoms, and rule out of any other alternative diagnoses (DeMaagd & 
Philip, 2015). PD can be clinically diagnosed by the presence of two or 
more of the cardinal motor symptoms including: rigidity (stiffness), 
bradykinesia (slowness of movement), or resting tremor (Cotterell, 
2018). There are no remarkable findings on MRI or CT studies typically 
for PD patients, and genetic markers are still being investigated to help 
with the diagnosis of PD (Capriotti & Terzakis, 2016). 
 
Treatment: Currently, there is no cure for PD so the goal of treatment is 
providing symptom management and maintaining or enhancing quality 
of life (Capriotti & Terzakis, 2016). Levodopa is the gold standard 
pharmacologic treatment for PD patients (Gopalakrishna & Alexander, 
2015). Deep brain stimulation is a procedure that can be beneficial for 
PD patients who have poorly controlled symptoms through medical 
management (Capriotti & Terzakis, 2016).  
Nursing Implications 
Delay the disease. (2017). Retrieved from 
http://www.delaythedisease.com/ 
APRN’s must focus their care on maintaining/enhancing the patient’s quality 
of life and independence by tailoring care and treating the symptomatic 
motor and nonmotor symptoms of the disease (Biercewicz et al., 2016).  
 
 
• Education on the medications  prescribed and the importance of taking 
medications on time as patients can go from “on” to “off” states quickly 
(Capriotti & Terzakis, 2016). 
• Help provide the patient with Physical Therapy or Occupational Therapy as a 
resource to help them maintain their ability to perform ADL’s and reduce the 
patient’s risks of falls (Biercewicz et al., 2016). 
• Educate the patient on the benefits that physical exercise can have. Research 
has begun to show that larger amounts of moderate-vigorous exercise may slow 
the progression of PD, potentially protect the brain from further cognitive 
impairment in later stages of the disease, and improve muscle strength and 
walking speed for those struggling with the typical motor symptoms of PD 
(Paillard, Rolland, & de Souto Barreto, 2015). 
•Dysphagia and constipation are two common symptoms PD patients may  
 experience related to autonomic dysfunction or as a side effect of medications. 
The APRN could help encourage the patient to speak with a speech therapist 
and/or nutritionist to help combat these symptoms/side effects (Capriotti & 
Terzakis, 2016). 
• APRN’s can utilize the Parkinson 
Neuropsychometric Dementia 
Assessment or The Folstein Mini-Mental 
Status Examination to evaluate cognitive 
impairment for PD patient’s (Capriotti & 
Terzakis, 2016). 
• Encourage the patient to discuss their 
experiences of living with PD with a 
psychiatrist to maintain or improve 
their mental/ emotional state 
(Biercewicz et al., 2016).  
 • If symptoms are not being managed 
well medically, the APRN could educate 
the patient about the option of the 
surgical intervention called Deep Brain 
Stimulation (Capriotti & Terzakis, 2016).  
 
• Dopamine plays a critical role in regulating motor functions and movements, therefore lack of 
dopamine will cause diminished coordination and difficulty managing many motor skills 
("Understanding parkinson's," 2019).  
• Dopamine also plays a critical role in cognition and controls things like memory and judgment, hence 
the reason why some individuals with PD may suffer from cognitive impairment later in the disease 
progression ("Understanding parkinson's," 2019).  
• By having knowledge about the possible genetic and environmental factors associated with  PD and 
its pathophysiology, health care providers can educate patients on potential protective factors 
including cholesterol levels and exercise (“Understanding parkinson’s,” 20119).  
• By understanding the pathophysiology of PD, healthcare providers can prescribe appropriate 
medications such as Levodopa or other dopaminergic medications to help manage  or improve 
symptoms by increasing the levels of dopamine in the brain(“Understanding parkinson’s,” 2019).  
• Health care providers must understand the pathophysiology of the disease in order to tailor and 
individualize care to help manage the patient's symptoms, maintain the patient's independence, and 
enhance their overall quality of life. 
 
 
